Every 8-K that Zura Bio Limited (ZURA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ZURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZURA filings page.
Zura Bio Limited furnished a corporate presentation dated August 17, 2026 for use at conferences and investor meetings. The presentation is included as Exhibit 99.1 and can be accessed via the News & Events section of the company’s investor relations website.
The information in this communication, including Exhibit 99.1, is furnished under Item 7.01 and is explicitly stated not to be deemed “filed” for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, nor incorporated by reference into other SEC filings except where specifically referenced.
Zura Bio Limited reported second quarter 2026 results and highlighted progress in its immunology pipeline centered on tibulizumab. Enrollment in both Phase 2 trials completed above target, with 247 participants in hidradenitis suppurativa (TibuSHIELD) and 91 in systemic sclerosis (TibuSURE). Topline data are expected in Q4 2026 and the first half of 2027, respectively, and a Phase 2 PMR study (NEXUS‑PMR) is planned by year-end 2026.
Cash and cash equivalents were $205.1 million as of June 30, 2026, up from $109.4 million at year-end 2025, and the company expects this to fund planned operations through at least the end of 2028. Second quarter 2026 R&D expense was $20.7 million and G&A expense was $8.6 million. Net loss for the quarter was $26.3 million, or $0.21 per share, compared with $16.0 million, or $0.17 per share, a year earlier. Shares outstanding were 95.4 million Class A ordinary shares as of June 30, 2026.
Zura Bio Limited furnished an updated corporate presentation dated July 1, 2026 for use at upcoming conferences and investor meetings. The presentation is provided as Exhibit 99.1 and is also available in the News & Events section of the company’s investor website.
The information is furnished under Item 7.01 of Form 8-K and is not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, nor incorporated by reference into other SEC filings unless specifically referenced.
Zura Bio Limited held its Annual General Meeting of Shareholders on June 17, 2026, where a quorum was present. Shareholders approved an amendment and restatement of the company’s 2023 Equity Incentive Plan, which became effective immediately upon approval.
All eight director nominees were elected to serve until the next annual general meeting or earlier departure. Shareholders also ratified the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026. Because the director slate, auditor ratification and equity plan proposals all received sufficient support, the contingency proposal to adjourn the meeting was not submitted for a vote.
Zura Bio Limited reported a board change. On May 20, 2026, director Someit Sidhu informed the company that he will resign from the board of directors, effective May 21, 2026. The company states that his resignation is not due to any disagreement regarding its operations, policies or practices.
Zura Bio Limited reported first quarter 2026 results and highlighted progress on its immunology pipeline. The company is advancing two Phase 2 trials of tibulizumab in hidradenitis suppurativa (TibuSHIELD) and systemic sclerosis (TibuSURE), with topline data expected in Q4 2026 and the first half of 2027, respectively.
Zura closed an underwritten public offering in February 2026 that generated approximately $144 million in gross proceeds, strengthening its balance sheet. Cash and cash equivalents were $225.6 million as of March 31, 2026, which management expects will fund planned operations through at least the end of 2028.
Research and development expenses rose to $14.7 million from $10.5 million a year earlier as tibulizumab programs progressed. General and administrative expenses increased to $10.8 million from $8.8 million, reflecting higher compensation and professional costs. Net loss widened to $24.2 million, or $0.22 per share, compared with $17.4 million, or $0.19 per share, in the first quarter of 2025.
Zura Bio Limited reported a leadership change in its finance function. On April 20, 2026, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer Eric Hyllengren was separated from the company, with the company stating the separation was not related to its financial or operating results or to any disagreements over operations or reporting practices. Under a Separation Agreement signed April 21, 2026, he will receive severance equal to three months of base salary and reimbursement of COBRA premiums for up to six months, contingent on his compliance with the agreement.
The board appointed Marlyn Mathew, the company’s Vice President, Finance and Accounting, as principal accounting officer and principal financial officer effective April 20, 2026. Her annual base salary was increased to $366,415. Mathew has led finance and accounting at Zura Bio since June 2022 and previously held controller roles at Immunovant. The company notes she has no related‑party arrangements or family relationships with directors or executive officers.
Zura Bio Limited reported full-year 2025 results and highlighted progress across its clinical pipeline and financing. The company posted a net loss of $68.7 million for 2025, compared with $52.4 million in 2024, as research and development spending increased to $42.1 million to advance Phase 2 tibulizumab trials.
Cash and cash equivalents were $109.4 million as of December 31, 2025, down from $176.5 million a year earlier. In February 2026, Zura completed an underwritten equity offering with gross proceeds of about $144 million, and now believes its cash can fund operations through at least the end of 2028.
The Phase 2 TibuSHIELD study in hidradenitis suppurativa expanded planned enrollment to 225 participants, with topline data expected in the fourth quarter of 2026. The TibuSURE Phase 2 study in systemic sclerosis is ongoing, with topline data anticipated in the first half of 2027. Leadership updates include appointing Sandeep Kulkarni, M.D., as Chief Executive Officer in January 2026 and adding two new board members in February 2026.
Zura Bio Limited furnished a new corporate presentation for investors and conferences dated March 10, 2026. The materials are provided under a Regulation FD disclosure to share updated information with the market.
The presentation is available as Exhibit 99.1 and can also be accessed through the company’s investor relations website in the “News & Events” section. The materials are furnished, not filed, and are not automatically incorporated into other SEC filings.
Zura Bio Limited filed a current report describing a press release about its Phase 2 TibuSURE study of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis. The company will present the study design as a poster at the 9th Systemic Sclerosis World Congress in Athens.
The global, randomized, double-blind, placebo-controlled Phase 2 trial is expected to enroll about 80 adults, treated every four weeks for 24 weeks, followed by a 28‑week open-label extension. The primary endpoint is change in modified Rodnan Skin Score at Week 24, with topline results anticipated in the first half of 2027.
Tibulizumab is an investigational dual-pathway antibody targeting IL-17A and BAFF. Zura highlights that no clinical efficacy or safety data will be presented in the poster; it focuses on study rationale and design only.
Zura Bio Limited filed an amended current report to update two legal exhibits tied to a prior disclosure. Amendment No. 1 replaces in full Exhibit 5.1, the opinion of Ogier (Cayman) LLP, and Exhibit 23.1, Ogier’s consent, which were originally filed with an earlier report. The amendment states that no other portions of the original report are changed, and it lists previously filed items such as the underwriting agreement, form of pre-funded warrant, and related press releases as unchanged exhibits.
Zura Bio Limited entered into an underwriting agreement for a public offering of equity. The company is issuing 18,200,000 Class A ordinary shares at $6.25 per share and pre-funded warrants to purchase 1,800,000 ordinary shares at $6.249 per warrant.
The underwriters received a 30-day option to buy up to an additional 3,000,000 ordinary shares at the public price, and this option was exercised in full. Zura expects net proceeds of approximately $134.6 million after underwriting discounts and expenses, with closing expected on February 26, 2026, subject to customary conditions.
As of December 31, 2025, Zura estimated cash and cash equivalents of about $109.4 million. After the offering, outstanding ordinary shares are stated as 94,875,460, based on 65,018,058 shares outstanding as of September 30, 2025 and additional shares issued to Athanor Capital, assuming no exercise of the pre-funded warrants.
Zura Bio Limited reported board changes and new director compensation terms. Neil Graham resigned from the board of directors on February 21, 2026, and the company states his resignation was not due to any disagreement with management, strategy, or operations.
On the same date, the board appointed two experienced immunology and drug development leaders, Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., as directors. Each will receive a prorated annual cash retainer of $40,000 and an initial stock option grant to purchase the lesser of 51,000 Class A ordinary shares or the number with an option value capped at $200,000, vesting over one year. They will also be eligible for similarly structured annual option grants for continued service. A press release with additional background on the new directors and Zura’s clinical-stage pipeline, including Phase 2 studies of tibulizumab (ZB-106) in hidradenitis suppurativa and systemic sclerosis, was furnished as an exhibit.
Zura Bio Limited furnished an updated corporate presentation dated February 11, 2026 that may be used at upcoming conferences and investor meetings. The full presentation is included as Exhibit 99.1 and can also be accessed via the News & Events section of the company’s investor website.
The company specifies that the material furnished under Item 7.01, including Exhibit 99.1, is provided under Regulation FD, is not considered “filed” for purposes of the Securities Exchange Act or Securities Act liability provisions, and is not automatically incorporated by reference into other SEC filings unless specifically referenced.
Zura Bio Limited announced a leadership transition. Robert Lisicki resigned as Chief Executive Officer, principal executive officer and director, effective January 21, 2026, after previously taking medical leave. Under a separation agreement, he will remain a non-executive employee through March 31, 2026 with transition pay of $72,000 on an annualized basis, a lump-sum severance equal to 12 months of base salary reduced by that transition pay, COBRA premiums for up to nine months, an extended 12‑month post-termination option exercise window, and accelerated vesting for 25% of the stock options granted to him on February 27, 2025.
The Board appointed director Dr. Sandeep Kulkarni as Chief Executive Officer and principal executive officer, with an annual base salary of $655,000 and a target bonus equal to 55% of base salary, and equity awards under the 2023 Equity Incentive Plan. Kim Davis stepped down from interim CEO duties and continues as Chief Operating Officer, Chief Legal Officer and Corporate Secretary. The Board also appointed Parvinder Thiara as a director, with a prorated $40,000 annual cash retainer and stock option grants tied to service under the Non-Employee Director Compensation Policy.
Zura Bio Limited furnished a new corporate presentation and issued a press release tied to its business outlook. The presentation, dated January 12, 2026, may be used at conferences and investor meetings and is available as Exhibit 99.1 and through the company’s investor website.
The press release, filed as Exhibit 99.2, discusses corporate and clinical trial updates and the company’s outlook for 2026, including its cash runway and expected topline data timelines for two ongoing Phase 2 studies of tibulizumab in hidradenitis suppurativa and systemic sclerosis. Both exhibits are referenced in this current report.
Zura Bio Limited reported that Arnout Ploos van Amstel resigned from its Board of Directors and from the Board’s Nominating and Governance Committee effective December 11, 2025. The company states that his decision is not due to any disagreement with its operations, policies or practices.
The disclosure centers on this board-level governance change. Zura Bio is organized in the Cayman Islands, is an emerging growth company, and its Class A ordinary shares trade on the Nasdaq Stock Market under the symbol ZURA.
Zura Bio Limited furnished a press release announcing its third quarter 2025 financial results. The release was provided as Exhibit 99.1 to a Form 8-K dated November 13, 2025. Under Item 2.02, the information (including Exhibit 99.1) is deemed furnished, not filed, and is not incorporated by reference except as specifically stated.
Zura Bio Limited reported a leadership change triggered by a medical leave. On October 8, 2025, Chief Executive Officer and Board member Robert Lisicki informed the company that he is taking a medical leave of absence effective October 10, 2025.
The Board appointed Kim Davis, currently Chief Operating Officer, Chief Legal Officer and Corporate Secretary, to serve as interim Chief Executive Officer and interim principal executive officer starting October 10, 2025, while she continues in her existing roles. The company notes that there are no special arrangements behind her appointment, no related-party transactions requiring disclosure, and no family relationships between Davis and any directors or executive officers.
Zura Bio Limited reported that its Board adopted an Executive Severance Benefit Plan covering certain employees, including current named executive officers. Under the plan, if an eligible executive is terminated without cause or resigns for good reason after at least 91 days of employment, the Chief Executive Officer may receive a lump sum equal to 12 months of base salary, while other named executive officers and certain executives may receive nine months of base salary.
If a qualifying termination occurs within 12 months after a change in control, the benefits increase. In that case, the Chief Executive Officer may receive 18 months of base salary, 150% of target annual bonus, a prorated bonus for the year of termination based on actual performance, and up to 18 months of COBRA or comparable health coverage reimbursement. Other named executive officers and certain executives may receive 12 months of base salary, 100% of target annual bonus, a prorated actual-performance bonus, and up to 12 months of COBRA or comparable coverage reimbursement.
Zura Bio Limited reported that it has prepared an updated corporate presentation as of September 4, 2025. The presentation may be used at conferences and investor meetings to explain the company’s business and outlook.
The updated deck is filed as Exhibit 99.1 and is also available in the News & Events section of Zura Bio’s investor website. The company notes that this material is being furnished under a disclosure item for investor information and is not considered filed for liability purposes under U.S. securities laws or automatically incorporated into other SEC filings.
Zura Bio Limited filed a current report to furnish a press release dated August 20, 2025. The company states that the information in Item 7.01 and Exhibit 99.1 is being provided under Regulation FD and is considered “furnished,” not “filed,” which means it is not subject to certain liability provisions of the Exchange Act unless later specifically incorporated by reference. The filing identifies the press release as Exhibit 99.1 and also includes a cover page interactive data file as Exhibit 104.
Zura Bio Limited furnished a press release announcing its second quarter 2025 financial results and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states the results disclosure is furnished under Item 2.02 rather than "filed," and the press release itself is incorporated by reference into the exhibit list.
The company also confirms its securities trading symbol and that it qualifies as an emerging growth company. No financial tables, specific revenue, earnings or other numeric results are included within the 8-K text; interested readers must refer to Exhibit 99.1 for the full press release content.
Zura Bio Limited (Nasdaq: ZURA) filed an 8-K announcing a leadership transition in its finance organization. The Board has appointed Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. Hyllengren brings more than two decades of biotech experience, most recently serving as CFO/COO of Atara Biotherapeutics and holding multiple senior finance roles at Amgen. His compensation package includes a $475,000 base salary, a target bonus equal to 40 % of salary, and an inducement option for 672,000 Class A shares that vests over four years.
Current CFO Verender Badial tendered his resignation on June 25, 2025. He will stay through the effective date and remain as a non-executive employee until July 31, 2025 to ensure continuity. A Settlement Agreement provides Badial with cash severance and benefits totaling roughly £295,000, accelerated vesting on options covering 186,561 shares, transfer restrictions on those shares for up to three years, and an extension of option exercise periods. Options for 303,100 shares granted on May 8, 2025 will be forfeited.
Key implications for investors:
- The company gains an experienced biotech finance executive with M&A, operations and capital-markets expertise.
- Management states the transition is not related to accounting disagreements, reducing concern over financial reporting integrity.
- Severance and inducement equity create modest near-term cash outflow and long-term dilution, but no immediate impact on operating results.
A press release dated July 1, 2025 regarding these changes was furnished as Exhibit 99.1.